Les Laboratoires Servier has been granted a patent for methods to treat gliomas with IDH1 or IDH2 mutations. The treatment involves administering a specific compound alongside radiation therapy or additional therapeutic agents to patients in need. GlobalData’s report on Les Laboratoires Servier gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Les Laboratoires Servier, Cancer treatment biomarkers was a key innovation area identified from patents. Les Laboratoires Servier's grant share as of July 2024 was 56%. Grant share is based on the ratio of number of grants to total number of patents.
Method for treating glioma with specific mutations
The granted patent US12064436B2 outlines a method for treating glioma associated with mutations in the IDH1 or IDH2 genes, which lead to the accumulation of R(-)-2-hydroxyglutarate. The treatment involves administering a specific compound, referred to as formula (I), to patients diagnosed with these mutations. The claims specify that the compound can be given in doses ranging from 10 to 50 mg per day. Additionally, the treatment may include radiation therapy, particularly x-ray radiation, administered at cumulative doses between 30 to 60 Gy. The patent also identifies specific mutations within the IDH1 and IDH2 genes, such as R132X, R140X, and R172X, among others, which are relevant to the treatment method.
Furthermore, the patent describes the potential for combination therapy, where the compound of formula (I) can be administered alongside other therapeutic agents, including temozolomide, bevacizumab, or gemcitabine. For temozolomide, the recommended dosage is between 150-200 mg/m² based on the patient's body surface area. The claims also allow for the administration of the compound in non-salt form, providing flexibility in formulation. Overall, the patent presents a comprehensive approach to treating glioma with specific genetic mutations, emphasizing both the primary compound and the potential for adjunctive therapies.
To know more about GlobalData’s detailed insights on Les Laboratoires Servier, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
